Care required when assigning dx codes for Zometa

Why This Topic Matters

Coverage and diagnosis coding for these therapies could determine whether claims were paid or denied, especially when the same medication was used for different clinical reasons. The article helps readers identify when contractor-specific policies, documentation, and diagnosis selection were being discussed in the coding guidance.

Article Sections

1. Zometa coding considerations

   Introduces the main clinical scenarios discussed for Zometa and frames the coding and payer-policy issues that follow. The section focuses on the general types of diagnoses and coverage questions involved.

2. Some payers okay 733.xx

   Summarizes payer variation and examples of contractor acceptance for certain osteoporosis-related diagnosis categories. It also notes the need to review local coverage policies carefully.

3. Abarelix

   Covers a separate prostate cancer drug and the general diagnosis-coding and policy considerations associated with it. The section also notes the contractor guidance and administration context discussed in the article.

4. NGS also revises related LCDs

   Describes another Medicare contractor’s local coverage guidance and how it relates to osteoporosis drugs and prostate cancer treatment effects. The section compares policy handling across diagnoses and contractor jurisdictions.